Regulatory T cells and inhibitory cytokines in autoimmunity

Current Opinion in Immunology

Volumn 21, Issue 6, 2009, Pages 612-618

  Bettini, Maria ^a   Vignali, Dario AA ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; INTERFERON REGULATORY FACTOR 4; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 27; INTERLEUKIN 6; INTERLEUKIN 7 RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; BACTERIAL IMMUNITY; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE RELEASE; DENDRITIC CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE FUNCTION; MULTIPLE SCLEROSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TH17 CELL; TH2 CELL; TH3 CELL;

ANIMALS; AUTOIMMUNITY; CYTOKINES; DIABETES MELLITUS, TYPE 1; HUMANS; MULTIPLE SCLEROSIS; T-LYMPHOCYTES, REGULATORY;

EID: 70449497739     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2009.09.011     Document Type: Review

References (66)

1. Sakaguchi S., Ono M., Setoguchi R., Yagi H., Hori S., Fehervari Z., Shimizu J., Takahashi T., and Nomura T. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 212 (2006) 8-27
2. Hellings N., Baree M., Verhoeven C., D'Hooghe M.B., Medaer R., Bernard C.C., Raus J., and Stinissen P. T-cell reactivity to multiple myelin antigens in multiple sclerosis patients and healthy controls. J Neurosci Res 63 (2001) 290-302
3. Vignali D.A., Collison L.W., and Workman C.J. How regulatory T cells work. Nat Rev Immunol 8 (2008) 523-532
4. Collison L.W., Pillai M.R., Chaturvedi V., and Vignali D.A. Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner. J Immunol 182 (2009) 6121-6128. This is the first paper to suggest that it is the induction of maximal suppression rather than suppression itself that is critically dependent on target cell contact.
5. Belkaid Y. Regulatory T cells and infection: a dangerous necessity. Nat Rev Immunol 7 (2007) 875-888
6. Izcue A., Coombes J.L., and Powrie F. Regulatory lymphocytes and intestinal inflammation. Annu Rev Immunol 27 (2009) 313-338
7. Chen Z., Herman A.E., Matos M., Mathis D., and Benoist C. Where CD4+CD25+ T reg cells impinge on autoimmune diabetes. J Exp Med 202 (2005) 1387-1397
8. McGeachy M.J., Stephens L.A., and Anderton S.M. Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system. J Immunol 175 (2005) 3025-3032
9. Korn T., Reddy J., Gao W., Bettelli E., Awasthi A., Petersen T.R., Backstrom B.T., Sobel R.A., Wucherpfennig K.W., Strom T.B., et al. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat Med 13 (2007) 423-431
10. McGeachy M.J., and Anderton S.M. Cytokines in the induction and resolution of experimental autoimmune encephalomyelitis. Cytokine 32 (2005) 81-84
11. Tritt M., Sgouroudis E., d'Hennezel E., Albanese A., and Piccirillo C.A. Functional waning of naturally occurring CD4+ regulatory T-cells contributes to the onset of autoimmune diabetes. Diabetes 57 (2008) 113-123
12. Mellanby R.J., Thomas D., Phillips J.M., and Cooke A. Diabetes in non-obese diabetic mice is not associated with quantitative changes in CD4+ CD25+ Foxp3+ regulatory T cells. Immunology 121 (2007) 15-28
13. D'Alise A.M., Auyeung V., Feuerer M., Nishio J., Fontenot J., Benoist C., and Mathis D. The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors. Proc Natl Acad Sci U S A 105 (2008) 19857-19862. This paper takes the spotlight away from possible defects in Treg number and function as a contributing factor in autoimmunity and instead points towards a defect in the effector T cell population, and manifests as hyperproliferation and perhaps resistance to Treg control.
14. Lindley S., Dayan C.M., Bishop A., Roep B.O., Peakman M., and Tree T.I. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 54 (2005) 92-99
15. Michel L., Berthelot L., Pettre S., Wiertlewski S., Lefrere F., Braudeau C., Brouard S., Soulillou J.P., and Laplaud D.A. Patients with relapsing-remitting multiple sclerosis have normal Treg function when cells expressing IL-7 receptor alpha-chain are excluded from the analysis. J Clin Invest 118 (2008) 3411-3419
16. Luczynski W., Stasiak-Barmuta A., Urban R., Urban M., Florys B., and Hryszko M. Lower percentages of T regulatory cells in children with type 1 diabetes - preliminary report. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw 15 (2009) 34-38
17. Tang Q., Adams J.Y., Penaranda C., Melli K., Piaggio E., Sgouroudis E., Piccirillo C.A., Salomon B.L., and Bluestone J.A. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28 (2008) 687-697. This study demonstrates that Tregs in pancreatic tissue site of NOD mice are prone to apoptosis because of insufficient levels of IL-2. This is the first study that links local tissue specific IL-2 levels to Treg function.
18. •].
19. regs, especially during autoimmune inflammation.
20. Yang X.O., Nurieva R., Martinez G.J., Kang H.S., Chung Y., Pappu B.P., Shah B., Chang S.H., Schluns K.S., Watowich S.S., et al. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 29 (2008) 44-56
21. Vignali D. How many mechanisms do regulatory T cells need?. Eur J Immunol 38 (2008) 908-911
22. •].
23. •] and this paper were the first to suggest that specific transcription factors mediate Treg control of specific T helper subsets.
24. Rubtsov Y.P., Rasmussen J.P., Chi E.Y., Fontenot J., Castelli L., Ye X., Treuting P., Siewe L., Roers A., Henderson Jr. W.R., et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 28 (2008) 546-558
25. Gregori S., Giarratana N., Smiroldo S., and Adorini L. Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development. J Immunol 171 (2003) 4040-4047
26. You S., Belghith M., Cobbold S., Alyanakian M.A., Gouarin C., Barriot S., Garcia C., Waldmann H., Bach J.F., and Chatenoud L. Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. Diabetes 54 (2005) 1415-1422
27. Schneider A., Rieck M., Sanda S., Pihoker C., Greenbaum C., and Buckner J.H. The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J Immunol 181 (2008) 7350-7355
28. Pasare C., and Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299 (2003) 1033-1036
29. Korn T., Mitsdoerffer M., Croxford A.L., Awasthi A., Dardalhon V.A., Galileos G., Vollmar P., Stritesky G.L., Kaplan M.H., Waisman A., et al. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A 105 (2008) 18460-18465
30. Veldhoen M., Hocking R.J., Atkins C.J., Locksley R.M., and Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24 (2006) 179-189
31. Stummvoll G.H., DiPaolo R.J., Huter E.N., Davidson T.S., Glass D., Ward J.M., and Shevach E.M. Th1, Th2, and Th17 effector T cell-induced autoimmune gastritis differs in pathological pattern and in susceptibility to suppression by regulatory T cells. J Immunol 181 (2008) 1908-1916
32. reg function in vivo in a model of colitis.
33. Shull M.M., Ormsby I., Kier A.B., Pawlowski S., Diebold R.J., Yin M., Allen R., Sidman C., Proetzel G., Calvin D., et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 359 (1992) 693-699
34. Kulkarni A.B., Huh C.G., Becker D., Geiser A., Lyght M., Flanders K.C., Roberts A.B., Sporn M.B., Ward J.M., and Karlsson S. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A 90 (1993) 770-774
35. Mosser D.M., and Zhang X. Interleukin-10: new perspectives on an old cytokine. Immunol Rev 226 (2008) 205-218
36. Kobayashi S., Yoshida K., Ward J.M., Letterio J.J., Longenecker G., Yaswen L., Mittleman B., Mozes E., Roberts A.B., Karlsson S., et al. Beta 2-microglobulin-deficient background ameliorates lethal phenotype of the TGF-beta 1 null mouse. J Immunol 163 (1999) 4013-4019
37. Letterio J.J., Geiser A.G., Kulkarni A.B., Dang H., Kong L., Nakabayashi T., Mackall C.L., Gress R.E., and Roberts A.B. Autoimmunity associated with TGF-beta1-deficiency in mice is dependent on MHC class II antigen expression. J Clin Invest 98 (1996) 2109-2119
38. Tonkin D.R., and Haskins K. Regulatory T cells enter the pancreas during suppression of type 1 diabetes and inhibit effector T cells and macrophages in a TGF-beta-dependent manner. Eur J Immunol 39 (2009) 1313-1322
39. Fahlen L., Read S., Gorelik L., Hurst S.D., Coffman R.L., Flavell R.A., and Powrie F. T cells that cannot respond to TGF-beta escape control by CD4(+)CD25(+) regulatory T cells. J Exp Med 201 (2005) 737-746
40. Joetham A., Takeda K., Taube C., Miyahara N., Matsubara S., Koya T., Rha Y.H., Dakhama A., and Gelfand E.W. Naturally occurring lung CD4(+)CD25(+) T cell regulation of airway allergic responses depends on IL-10 induction of TGF-beta. J Immunol 178 (2007) 1433-1442
41. Strauss L., Bergmann C., Szczepanski M., Gooding W., Johnson J.T., and Whiteside T.L. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res 13 (2007) 4345-4354
42. Li M.O., Wan Y.Y., and Flavell R.A. T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity 26 (2007) 579-591
43. Marie J.C., Liggitt D., and Rudensky A.Y. Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-beta receptor. Immunity 25 (2006) 441-454
44. Moore K.W., de Waal Malefyt R., Coffman R.L., and O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19 (2001) 683-765
45. Kuhn R., Lohler J., Rennick D., Rajewsky K., and Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75 (1993) 263-274
46. Spencer S.D., Di Marco F., Hooley J., Pitts-Meek S., Bauer M., Ryan A.M., Sordat B., Gibbs V.C., and Aguet M. The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor. J Exp Med 187 (1998) 571-578
47. Selvaraj R.K., and Geiger T.L. Mitigation of experimental allergic encephalomyelitis by TGF-beta induced Foxp3+ regulatory T lymphocytes through the induction of anergy and infectious tolerance. J Immunol 180 (2008) 2830-2838
48. Uhlig H.H., Coombes J., Mottet C., Izcue A., Thompson C., Fanger A., Tannapfel A., Fontenot J.D., Ramsdell F., and Powrie F. Characterization of Foxp3+CD4+CD25+ and IL-10-secreting CD4+CD25+ T cells during cure of colitis. J Immunol 177 (2006) 5852-5860
49. Allan S.E., Broady R., Gregori S., Himmel M.E., Locke N., Roncarolo M.G., Bacchetta R., and Levings M.K. CD4+ T-regulatory cells: toward therapy for human diseases. Immunol Rev 223 (2008) 391-421
50. Collison L.W., and Vignali D.A. Interleukin-35: odd one out or part of the family?. Immunol Rev 226 (2008) 248-262
51. El Kasmi K.C., Smith A.M., Williams L., Neale G., Panopoulos A.D., Watowich S.S., Hacker H., Foxwell B.M., and Murray P.J. Cutting edge: a transcriptional repressor and corepressor induced by the STAT3-regulated anti-inflammatory signaling pathway. J Immunol 179 (2007) 7215-7219
52. Tang Q., and Bluestone J.A. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol 9 (2008) 239-244
53. Andersson J., Tran D.Q., Pesu M., Davidson T.S., Ramsey H., O'Shea J.J., and Shevach E.M. CD4+ FoxP3+ regulatory T cells confer infectious tolerance in a TGF-beta-dependent manner. J Exp Med 205 (2008) 1975-1981. In this study, the authors demonstrate that Treg cells can confer infectious tolerance by inducing new CD4+FoxP3+ T cells in TGFβ-dependant mechanism.
54. Maynard C.L., Hatton R.D., Helms W.S., Oliver J.R., Stephensen C.B., and Weaver C.T. Contrasting roles for all-trans retinoic acid in TGF-beta-mediated induction of Foxp3 and Il10 genes in developing regulatory T cells. J Exp Med 206 (2009) 343-357. In this study the authors report that retinoic acid preferentially induces Foxp3+ Treg cells and inhibits generation of IL-10 producing regulatory cells.
55. Sun C.M., Hall J.A., Blank R.B., Bouladoux N., Oukka M., Mora J.R., and Belkaid Y. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J Exp Med 204 (2007) 1775-1785
56. Coombes J.L., Siddiqui K.R., Arancibia-Carcamo C.V., Hall J., Sun C.M., Belkaid Y., and Powrie F. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med 204 (2007) 1757-1764
57. Hill J.A., Hall J.A., Sun C.M., Cai Q., Ghyselinck N., Chambon P., Belkaid Y., Mathis D., and Benoist C. Retinoic acid enhances Foxp3 induction indirectly by relieving inhibition from CD4+CD44hi cells. Immunity 29 (2008) 758-770. This study reports that retinoic acid promotes TGFβ induced Treg development by inhibiting the production of a set of cytokines (IFNγ, IL-21, IL-4) produced by activated CD4+CD44+ T cell population.
58. Mucida D., Park Y., Kim G., Turovskaya O., Scott I., Kronenberg M., and Cheroutre H. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 317 (2007) 256-260. This is the first study reporting that a metabolite retinoic acid can shift the balance between Foxp3+ regulatory and Th17 inflammatory populations.
59. Benson M.J., Pino-Lagos K., Rosemblatt M., and Noelle R.J. All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J Exp Med 204 (2007) 1765-1774
60. Yamazaki S., Dudziak D., Heidkamp G.F., Fiorese C., Bonito A.J., Inaba K., Nussenzweig M.C., and Steinman R.M. CD8+ CD205+ splenic dendritic cells are specialized to induce Foxp3+ regulatory T cells. J Immunol 181 (2008) 6923-6933
61. Belkaid Y., and Tarbell K. Regulatory T cells in the control of host-microorganism interactions. Annu Rev Immunol 27 (2009) 551-589
62. Lennon G.B., Bettini M., Burton A.R., Vincent E., Arnold P.Y., Santamaria P., and Vignali D.A. T cell islet accumulation in type I diabetes is a tightly-regulated, cell-autonomous event. Immunity (2009) 10.1016/j.immuni.2009.07.008
63. Chatenoud L., and Bluestone J.A. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 7 (2007) 622-632
64. Brusko T., and Bluestone J. Clinical application of regulatory T cells for treatment of type 1 diabetes and transplantation. Eur J Immunol 38 (2008) 931-934
65. Braat H., Rottiers P., Hommes D.W., Huyghebaert N., Remaut E., Remon J.P., van Deventer S.J., Neirynck S., Peppelenbosch M.P., and Steidler L. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 4 (2006) 754-759
66. Bhavsar M.D., and Amiji M.M. Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease. Gene Ther 15 (2008) 1200-1209